Physician profile
Willis E Godin
NPI 1508944570
$3,475.34
in general payments reported to CMS, 2019-2025
20 companies · $29.92 in 2025
The $29.92 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $356 · 2021: $926 · 2022: $920 · 2023: $866 · 2024: $129 · 2025: $29.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,025.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $860.69 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $392.38 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $377.18 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.42 | 2020-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $350.59 | 2019-2024 | Eliquis, Camzyos |
| Amgen INC. | $278.09 | 2020-2023 | Repatha |
| Merck Sharp & Dohme LLC | $152.58 | 2021-2023 | Verquvo |
| Pfizer INC. | $121.66 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $120.16 | 2020-2023 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $84.35 | 2020-2023 | Uptravi, Opsumit |
| Sanofi-Aventis U.S. LLC | $69.45 | 2019-2023 | |
| Boston Scientific Corporation | $58.56 | 2022-2024 | Watchman Flx |
| Esperion Therapeutics, INC. | $50.64 | 2020-2023 | Nexletol |
| Impulse Dynamics (USA) INC. | $43.30 | 2023 | Optimizer |
| Kestra Medical Technology Services, INC. | $36.94 | 2024 | Assure Wcd |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $33.49 | 2022 | |
| Abbott Laboratories | $24.30 | 2021 | |
| Scpharmaceuticals INC. | $20.82 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $14.55 | 2023 | Inpefa |
| Novo Nordisk INC | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willis Godin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.